Jeannie M Arruda

This inventor holds 28 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Lysophosphatidic Acid Antagonists. Top assignees: Amira Pharmaceuticals, Inc., Panmira Pharmaceuticals, LLC, Merck Sharp + Dohme Corp.. Active years: 2006-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeannie M Arruda. Retrieved from https://idiyas.com/inventor/jeannie-m-arruda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 8)

% Patents Active = 53.6

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 6.6

ph-index = 8

Forward Citations = 161(Granted Patents)

Location History:

La Jolla, CA (US) (2011 - 2013)
San Diego, CA (US) (2006 - 2018)

Company Filing History:

12 out of 23

Amira Pharmaceuticals, Inc.

patents

9 out of 23

Panmira Pharmaceuticals, LLC

patents

4 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2006-2018

Loading Chart...

Areas of Expertise:

Lysophosphatidic Acid

Antagonists

FLAP Inhibitors

Polycyclic Compounds

Thiazolyl Compounds

Metabotropic Receptors

Prostaglandin D2

5-Lipoxygenase

Akt Activity Inhibitors

Diaryl-Furanone

MGlur5

Prodrugs

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10000456 - Polycyclic compounds as lysophosphatidic acid receptor antagonists (2018-06-19),

2. 9624182 - Compounds as lysophosphatidic acid receptor antagonists (2017-04-18),

3. 9090573 - Compounds as lysophosphatidic acid receptor antagonists (2015-07-28),

4. 8778983 - Polycyclic compounds as lysophosphatidic acid receptor antagonists (2014-07-15),

5. 8664220 - Polycyclic compounds as lysophosphatidic acid receptor antagonists (2014-03-04),

6. 8609852 - Thiazolyl mGluR5 antagonists and methods for their use (2013-12-17),

7. 8546431 - 5-lipoxygenase-activating protein (FLAP) inhibitors (2013-10-01),

8. 8524748 - [object Object] (2013-09-03),

9. 8497381 - [object Object] (2013-07-30),

10. 8455499 - Alkyne antagonists of lysophosphatidic acid receptors (2013-06-04),

11. 8440707 - Antagonists of lysophosphatidic acid receptors (2013-05-14),

12. 8399666 - 5-lipoxygenase-activating protein (FLAP) inhibitors (2013-03-19),

13. 8362044 - N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors (2013-01-29),

14. 8273780 - Polycyclic antagonists of lysophosphatidic acid receptors (2012-09-25),

15. 8247602 - [object Object] (2012-08-21),

Title: Jeannie M Arruda: Pioneering Pharmaceuticals Innovations

Introduction

Jeannie M Arruda, a talented inventor hailing from San Diego, CA, has made significant contributions to the field of pharmaceuticals with a total of 28 patents to his name. His innovative work has focused on developing compounds as lysophosphatidic acid receptor antagonists, with a goal of treating LPA-dependent or LPA-mediated conditions and diseases.

Latest Patents

Arruda's latest patents showcase his dedication to advancing pharmaceutical solutions. The patented compounds act as antagonists of lysophosphatidic receptor(s) and have paved the way for the development of pharmaceutical compositions and medicaments for the treatment of various conditions.

Career Highlights

Throughout his career, Arruda has lent his expertise to esteemed companies such as Amira Pharmaceuticals, Inc. and Panmira Pharmaceuticals, LLC. His work in these organizations has been instrumental in driving forward innovations in the pharmaceutical industry.

Collaborations

Collaboration plays a crucial role in the world of inventions, and Arruda has had the privilege of working alongside accomplished individuals like Thomas Jon Seiders and John Howard Hutchinson. Together, they have pushed the boundaries of pharmaceutical research and development.

Conclusion

Jeannie M Arruda's journey as an inventor in the pharmaceutical sector is a testament to his commitment to innovation and advancements in healthcare. His patents and collaborations stand as a legacy of his impactful contributions to the field, and his work continues to inspire future generations of inventors.

Profile summary based on public USPTO records.